甘精胰岛素会以剂量依赖的方式增加癌症风险（长期使用会增加乳腺癌风险）。
原始表述
وفي تحليل Hemkens الألماني على 127 ألف مريض، رفع جلارجين خطر السرطان بشكل يتناسب مع الجرعة.
按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。
译文
甘精胰岛素会以剂量依赖的方式增加癌症风险（长期使用会增加乳腺癌风险）。
出处
- 来源状态
- 档案网站编辑
- 归属
- Archive editors (not Elawady)
- 出处
- https://eltayebat.com/rule/insulin-injections/
- 归属的不确定性
- Editorial narrative and study selection written by the archive operators.
- 所声称的机制
Mitogenic (growth-promoting) properties of glargine via IGF-1 receptor.
- 所声称的健康影响
Cancer, breast cancer
- 涉及人群
Insulin-treated diabetes
- Elawady 设定的地域限制
none found
科学评估
基本错误 – 该说法的主要部分没有证据支持，或被严重夸大。
证据确定性: 中 – 进一步研究仍可能影响该评估。
1. 说法是什么？
Glargine causes cancer, dose-dependently.
2. 哪些内容可证实是正确的？
Hemkens et al. (127,031 German patients, mean follow-up 1.63 years) found, after dose adjustment, HR 1.09/1.19/1.31 for 10/30/50 IU/day of glargine vs human insulin (A-INS-04); this triggered regulatory reviews in 2009. Jonasson et al. found a higher breast-cancer RR (1.99) in women using glargine alone (A-INS-05); Suissa et al. found a possible increase after >5 years in women previously on insulin (HR 2.7, based on 10 cases) (A-INS-06). These signals are real but hypothesis-generating.
3. 哪些内容是错误或夸大的？
In Hemkens et al. crude cancer incidence was lower with glargine (2.14 vs 2.50 per 100 person-years; unadjusted HR 0.85); the excess appeared only after modelling with a time-at-risk-based dose, was concentrated in users of >40 IU/day, and higher dose was associated with cancer for all insulin types; the authors state that causality cannot be shown (A-INS-04). Jonasson et al. found no increase for all malignancies (RR 1.07, 0.91-1.27); the breast signal (25 cases) was absent in users of glargine plus other insulins, showed no dose trend, and the authors suggest chance (A-INS-05). Suissa et al. found no overall increase (HR 1.0, 0.7-1.4) and none in the first 5 years (HR 0.9), with no dose data (A-INS-06). The randomised ORIGIN trial found no difference in cancers (HR 1.00) (A-INS-07) and, in its cancer substudy, identical incidence, cancer mortality and site-specific cancers (I-INS-05). A meta-analysis found lower odds of cancer with glargine (OR 0.81) and no breast-cancer increase (OR 0.99), with very low-quality evidence (I-INS-06).
4. 哪些内容仍不明确？
Very long-term (>10 years) breast-cancer risk has limited data. A UK CPRD cohort found HR 2.23 (1.32-3.77) for breast cancer after >5 years of glargine versus NPH, mainly in women who had used other insulins before (I-INS-124), whereas a Medicare new-user cohort of 203,159 glargine initiators found no increase by duration or dose (HR 0.97, 0.88-1.06) (I-INS-125) and a CPRD analysis found no association in insulin-naive women (HR 1.06 after >=5 years) (I-INS-127). A systematic review judged the observational evidence methodologically weak, with uncertainty remaining particularly for breast cancer (I-INS-126).
5. 哪些研究支持该说法？
No study clearly supports the dose-dependent cancer claim. Partly: I-INS-124 (long-term breast-cancer signal in prevalent users). Mixed: A-INS-04 (model-dependent dose signal), A-INS-05, A-INS-06, I-INS-126, I-INS-127.
6. 哪些研究与该说法相矛盾？
A-INS-07, I-INS-05 (ORIGIN RCT), I-INS-125 (large new-user cohort: no duration or dose effect), I-INS-06.
7. 对德国和欧洲而言情况如何？
The signal came from German data (AOK) and was reviewed by European regulators in 2009 (EMA statement not fetched in this audit; verified: false). Glargine remains approved in the EU.
8. 关于埃及的已知情况是什么？
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
9. 合理的实际结论是什么？
2009年关于甘精胰岛素致癌的警报并未得到随机对照证据的证实。正在使用甘精胰岛素的人不应因为害怕癌症而停用。
评估详情
- 证据确定性的依据
The 2009 observational signal (Hemkens) was real but inconsistent (Swedish and UK data showed no overall increase); the subsequent randomised ORIGIN cancer analysis (12,537 people, 953 cancer events, 6.2 years) found identical cancer incidence (1.32 vs 1.32 per 100 person-years), and a meta-analysis of 11 studies did not support a link (very low quality). Moderate rather than high certainty because the breast-cancer question for very long use was not fully resolved.
- 来源质量
Archive editorial quoting a German insurance cohort.
- 地区可推广性
German, Swedish, UK data; directly relevant to Europe.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
过度解读 – 确有真实的发现，但该说法从中引申出的结论超出了数据所能支持的范围（例如把关联当作因果、把动物数据套用到人身上、把小效应说成大效应）。
研究问题: Does insulin glargine increase cancer risk dose-dependently, and does long-term use increase breast cancer?
研究问题详解 (PECO)
- 人群
- People with diabetes using insulin
- 干预或暴露
- Insulin glargine (dose, duration)
- 对照
- NPH or other insulins
- 地域范围
- universal biology
- 结局指标
- Any cancer
- Breast cancer
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
Long-term glargine use and breast cancer in UK women
UK CPRD cohort: long-term glargine and breast cancer.
- 实际结果
- HR 2.23 (1.32-3.77) after >5 years vs NPH.
- 方法学质量
- moderate (cohort)
- 相关性
- direct for long-term breast cancer
- 局限
- Prevalent users; same data source/group as A-INS-06.
German insurance study on glargine and cancer
Hemkens LG et al.. Diabetologia 2009 · PMID 19565214 · DOI 10.1007/s00125-009-1418-4 队列研究全文，含结构化偏倚风险评估German cohort (Hemkens).
- 实际结果
- Dose-adjusted HR 1.31 at 50 IU/day.
- 方法学质量
- low (model-dependent)
- 相关性
- direct
- 局限
- Crude HR 0.85.
哪些证据不支持该说法？
Long-term insulin glargine in early diabetes (ORIGIN)
ORIGIN Trial Investigators; Gerstein HC et al.. N Engl J Med 2012 · PMID 22686416 · DOI 10.1056/NEJMoa1203858 随机对照试验全文，含结构化偏倚风险评估ORIGIN RCT.
- 实际结果
- Cancer HR 1.00 (0.88-1.13) over 6.2 years.
- 方法学质量
- high
- 相关性
- direct for overall cancer
- 局限
- Not powered for breast cancer beyond 6 years.
Glargine and breast cancer in older US women
Medicare new-user cohort (203,159 glargine initiators).
- 实际结果
- Breast cancer HR 0.97 (0.88-1.06); no dose or duration effect.
- 方法学质量
- high (large new-user cohort)
- 相关性
- direct
- 局限
- Older women.
Glargine, prior insulin use and breast cancer
CPRD: insulin-naive women.
- 实际结果
- HR 1.06 (0.48-2.33) after >=5 years.
- 方法学质量
- moderate
- 相关性
- direct
- 局限
- Small numbers.
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Glargine does not increase overall cancer risk dose-dependently; a long-term breast-cancer signal exists in some UK prevalent-user analyses but is not confirmed in larger new-user cohorts.
为什么有些研究权重更大
RCT and large new-user cohorts outweigh prevalent-user cohorts with time-related biases.
因果关系是否已确立？ 尚未确立 No consistent dose-response; signal confined to prevalent users/switchers.
仍存在的不确定性
Very long-term (>10 years) breast cancer risk in younger women.
合理的结论
Mostly false; breast-cancer part unresolved.
为什么研究结果看起来互相矛盾？
Wu 2017 and Suissa 2011 (UK CPRD, prevalent users) vs Bradley 2020 (Medicare new users) and Peeters 2016 (CPRD, insulin-naive): differences in prevalent-user bias, prior insulin exposure and age explain much of the conflict.
这是否取决于国家？
- 一般生物学效应
- European (German, UK) and US data; glargine remains approved in the EU.
- 饮食习惯
- Egyptian and European diets differ, but no dietary pattern replaces insulin in insulin-deficient diabetes.
- 食品原产地
- Not relevant.
- 污染物
- Not relevant.
- 本国生产条件
- Not relevant.
- 法律规则
- Insulin is an essential medicine (WHO list) in Egypt and the EU; prescription rules not relevant to the scientific question.
- 实际监测数据
- Egyptian/Middle Eastern data show severe DKA is common at presentation in children (I-INS-115, I-INS-114); no data on outcomes among Tayebat followers.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- CI symmetry and illustrative absolute excess – CIs symmetric; if causal, about 1.5-4 extra breast cancers per 1000 person-years (illustrative, not reported) 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Overall cancer incidence with glargine
- 起始等级
- 高（随机试验）
- 降级理由
- imprecision for breast cancer beyond 6 years
- 结果
- 中
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- ADA: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (I-ODD-16) (2026) · 原始文献
'Insulin treatment is essential for individuals with type 1 diabetes'; insulin to be considered in T2D when A1C >10%, glucose >=300 mg/dL or catabolic features (as recorded for I-ODD-16).
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| PubMed | 2026年10月26日 | "insulin glargine" AND (cancer OR "breast cancer") AND (cohort) AND (multinational OR "five European" OR Nordic OR "long-term") | 双向 | 7 | |
| PubMed | 2026年10月26日 | ("insulin glargine" OR "long-acting insulin analog*") AND "breast cancer" AND (meta-analysis[pt] OR systematic review[pt]) | 双向 | 5 | |
| Europe PMC | 2026年10月26日 | (TITLE:"glargine") AND (TITLE:"cancer") AND PUB_YEAR:[2013 TO 2026] | 双向 | 11 |
核查深度如何？
11 项相关研究：5 项核查了全文（其中 5 项进行了结构化偏倚风险评估），6 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 基本错误 (中)
- 2026年10月26日 · 第 4 阶段（系统证据审查） · 在扩展证据后重新审查；评定结论不变: 基本错误 (中)
New supporting (Wu 2017) and contradicting (Bradley 2020, Peeters 2016) cohorts balance; the overall-cancer and dose parts remain contradicted by RCT and large cohorts; breast cancer long-term remains uncertain.
新来源: I-INS-124 I-INS-125 I-INS-126 I-INS-127
通俗解释
2009年，一项德国数据库研究提示，长效胰岛素甘精胰岛素可能会增加癌症风险。其他研究并没有发现同样的结果，而一项对超过12,000人随访六年的大型随机对照试验发现，使用和不使用甘精胰岛素的人癌症发生率完全相同。因此，早期的警报并未得到证实。
与该说法相关的研究
支持该说法的研究 (1)
-
Long-term glargine use and breast cancer in UK women
Wu JW et al.. J Clin Oncol 2017 · PMID 28953430 · DOI 10.1200/JCO.2017.73.4491队列研究独立交叉核查已核查摘要★ 关键研究After more than 5 years, glargine users had about twice the breast-cancer rate of NPH users, mainly among women who had used other insulin before.
Long-term glargine associated with breast cancer (HR 2.23 after >5 years); not replicated in new-user cohorts.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Study long-term glargine and breast cancer.
- 研究是如何开展的？
UK database cohort.
- 研究了多少人、动物或样本？
22,395 women.
- 实际发现了什么？
HR 1.44 overall; 2.23 after >5 years.
- 观察到的效应有多大？
About 1.5-4 extra cases per 1000 person-years if causal (illustrative).
- 研究结果对日常生活意味着什么？
A possible long-term signal that needs confirmation.
- 该研究有哪些局限？
Observational; not replicated.
- 它对 Elawady 的具体说法说明了什么？
Partly supports the breast-cancer part.
- 研究结果是否适用于德国和欧洲？
UK data.
- 从该研究中明确不能得出什么结论？
Cannot prove glargine causes breast cancer.
该组中没有被标记为关键研究的研究。
与该说法相矛盾或限制该说法的研究 (4)
-
Long-term insulin glargine in early diabetes (ORIGIN)
ORIGIN Trial Investigators; Gerstein HC et al.. N Engl J Med 2012 · PMID 22686416 · DOI 10.1056/NEJMoa1203858随机对照试验被 Tayebat 档案网站引用全文，含结构化偏倚风险评估★ 关键研究Over six years insulin did not change heart attacks, strokes or cancers, but caused more low-sugar episodes and 2 kg weight difference.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Does basal insulin glargine targeting normal fasting glucose reduce CV events in dysglycaemia?
- 研究是如何开展的？
International multicentre RCT, 2x2 factorial (ORIGIN)
- 研究了多少人、动物或样本？
12,537; CV risk factors plus IFG, IGT or type 2 diabetes; mean age 63.5
- 实际发现了什么？
Neutral CV and cancer outcomes; more hypoglycaemia, slight weight gain.
- 观察到的效应有多大？
HR 1.02 CV; HR 1.00 cancer
- 研究结果对日常生活意味着什么？
Insulin itself did not cause heart disease or cancer in this large trial.
- 该研究有哪些局限？
Open-label; funded by the glargine manufacturer; early-diabetes population on moderate doses (~28 units/day for 70 kg).
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
- 从该研究中明确不能得出什么结论？
Safety in very high-dose, late-stage type 2 diabetes.
-
Glargine and cancer in a randomised trial
Bordeleau L et al.. Diabetes Care 2014 · PMID 24574355 · DOI 10.2337/dc13-1468随机对照试验独立交叉核查已核查摘要★ 关键研究Cancer rates were identical with glargine and standard care (1.32 per 100 person-years each).
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Effect of glargine and n-3 fatty acids on incident cancers
- 研究是如何开展的？
Cancer substudy of the ORIGIN 2x2 factorial RCT
- 研究了多少人、动物或样本？
12,537 (953 cancer events); Dysglycaemia with high CV risk, mean age 63.5
- 实际发现了什么？
No difference in any cancer outcome.
- 观察到的效应有多大？
1.32 vs 1.32 per 100 PY
- 研究结果对日常生活意味着什么？
Glargine does not increase cancer within 6 years.
- 该研究有哪些局限？
Industry funding; 6 years may be short for some cancers
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
Multinational trial including European sites or directly applicable to EU practice.
- 从该研究中明确不能得出什么结论？
Effects after many decades.
-
Pooled studies of glargine and cancer
Tang X et al.. PLoS One 2012 · PMID 23284776 · DOI 10.1371/journal.pone.0051814Meta分析独立交叉核查全文，含结构化偏倚风险评估Glargine was not linked to more cancer, including breast cancer.
该研究是否支持这一具体说法？ 否 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Insulin glargine and cancer incidence
- 研究是如何开展的？
Meta-analysis of observational studies and RCTs with GRADE
- 研究了多少人、动物或样本？
11 studies; 448,928 subjects; Diabetes patients
- 实际发现了什么？
OR 0.81 any cancer.
- 观察到的效应有多大？
OR 0.81 (0.68-0.98)
- 研究结果对日常生活意味着什么？
No cancer increase.
- 该研究有哪些局限？
Mostly short-term observational data; very high heterogeneity; no study quality assessment; dose and long-term use not analysed; very low certainty.
- 它对 Elawady 的具体说法说明了什么？
Contradicts C-INS-06.
- 研究结果是否适用于德国和欧洲？
Includes European cohorts.
- 从该研究中明确不能得出什么结论？
That glargine protects against cancer, or anything about dose-dependent or long-term (>5 years) breast cancer risk.
-
Glargine and breast cancer in older US women
Bradley MC et al.. Diabetes Care 2020 · PMID 32075848 · DOI 10.2337/dc19-0614队列研究独立交叉核查已核查摘要★ 关键研究Among more than 300,000 women starting insulin, glargine users did not have more breast cancer, even with longer use or higher doses.
No breast cancer increase by duration or dose in 203,159 glargine initiators.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare breast cancer by insulin type.
- 研究是如何开展的？
Medicare new-user cohort.
- 研究了多少人、动物或样本？
317,559 women >=65.
- 实际发现了什么？
HR 0.97 vs NPH; no dose or duration effect.
- 观察到的效应有多大？
HR 0.97 (0.88-1.06).
- 研究结果对日常生活意味着什么？
Glargine does not appear to raise breast cancer risk.
- 该研究有哪些局限？
Older women only.
- 它对 Elawady 的具体说法说明了什么？
Contradicts dose-dependent cancer claim.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Cannot exclude small effects in younger women.
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (6)
-
Review: obesity and cancer
Calle EE et al.. Nat Rev Cancer 2004 · PMID 15286738 · DOI 10.1038/nrc1408叙述性综述被 Tayebat 档案网站引用已核查摘要Not assessed (no abstract available).
该研究是否支持这一具体说法？ 不明确 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Epidemiology and mechanisms linking overweight/obesity and cancer
- 研究是如何开展的？
Narrative review (no abstract in PubMed; not read)
- 研究了多少人、动物或样本？
not applicable; not applicable
- 实际发现了什么？
Not assessed.
- 观察到的效应有多大？
not applicable
- 研究结果对日常生活意味着什么？
Not assessable.
- 该研究有哪些局限？
Narrative review; Not read
- 它对 Elawady 的具体说法说明了什么？
Indirect background for C-INS-06.
- 研究结果是否适用于德国和欧洲？
not applicable
- 从该研究中明确不能得出什么结论？
Anything about insulin injections.
-
German insurance study on glargine and cancer
Hemkens LG et al.. Diabetologia 2009 · PMID 19565214 · DOI 10.1007/s00125-009-1418-4队列研究被 Tayebat 档案网站引用全文，含结构化偏倚风险评估★ 关键研究Without adjustment glargine users actually had slightly fewer cancers; only after statistical dose adjustment did glargine look somewhat worse, and follow-up was under 2 years.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Cancer and mortality risk with human insulin vs insulin analogues
- 研究是如何开展的？
Retrospective cohort from statutory health insurance claims (AOK)
- 研究了多少人、动物或样本？
127,031; Patients starting insulin monotherapy without known cancer
- 实际发现了什么？
Dose-adjusted cancer HR up to 1.31 for glargine; no increase for other analogues.
- 观察到的效应有多大？
Crude incidence 2.14 (glargine) vs 2.50 (human insulin) per 100 patient-years; dose-adjusted HR 1.09-1.31.
- 研究结果对日常生活意味着什么？
An early warning signal that later trials did not confirm.
- 该研究有哪些局限？
Follow-up about 1.6 years; result reverses with dose adjustment; dose computed over time at risk; no data on BMI, smoking, diabetes duration; groups clinically different.
- 它对 Elawady 的具体说法说明了什么？
Main support for C-INS-06.
- 研究结果是否适用于德国和欧洲？
German data; directly relevant.
- 从该研究中明确不能得出什么结论？
That glargine causes cancer.
-
Swedish study of glargine and cancer
Jonasson JM et al.. Diabetologia 2009 · PMID 19588120 · DOI 10.1007/s00125-009-1444-2队列研究被 Tayebat 档案网站引用全文，含结构化偏倚风险评估Overall cancer rates were the same; women using only glargine had more breast cancer (25 cases), which the authors say may be chance.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Short-term cancer incidence in glargine users (requested by EASD)
- 研究是如何开展的？
Nationwide register-based cohort
- 研究了多少人、动物或样本？
114,841; Insulin users in Sweden
- 实际发现了什么？
Any cancer RR 1.07 (n.s.); breast RR 1.99 in glargine-only users.
- 观察到的效应有多大？
All cancers RR 1.07 (0.91-1.27); breast cancer RR 1.99 in glargine-only women (5.0 vs 2.6 per 1,000 person-years).
- 研究结果对日常生活意味着什么？
No clear overall cancer risk.
- 该研究有哪些局限？
Only 2 years follow-up; breast signal based on 25 cases in one of many comparisons; no dose-response; many missing BMI/smoking data.
- 它对 Elawady 的具体说法说明了什么？
Limits C-INS-06 (overall null).
- 研究结果是否适用于德国和欧洲？
Swedish data; directly relevant.
- 从该研究中明确不能得出什么结论？
Causation.
-
Glargine and breast cancer in UK women
Suissa S et al.. Diabetologia 2011 · PMID 21614572 · DOI 10.1007/s00125-011-2190-9队列研究被 Tayebat 档案网站引用全文，含结构化偏倚风险评估No increase in breast cancer during the first five years; a possible increase later in a subgroup.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Long-term glargine use and breast cancer
- 研究是如何开展的？
Matched cohort in UK GPRD
- 研究了多少人、动物或样本？
15,227 (4,579 glargine); Women >=40 with type 2 diabetes on insulin
- 实际发现了什么？
Overall HR 1.0; no increase in first 5 years; HR 2.7 after >5 years only in women already on insulin before glargine (10 cases).
- 观察到的效应有多大？
Overall HR 1.0 (0.7-1.4); first 5 years HR 0.9 (0.7-1.3).
- 研究结果对日常生活意味着什么？
Possible long-term question, not established.
- 该研究有哪些局限？
Long-term signal based on 10 cases in one subgroup; chance possible; no dose data; some baseline differences (e.g. HRT use).
- 它对 Elawady 的具体说法说明了什么？
Mixed for C-INS-06.
- 研究结果是否适用于德国和欧洲？
UK data.
- 从该研究中明确不能得出什么结论？
Causation.
-
How good is the evidence on long-acting insulin and cancer?
Wu JW et al.. Diabetes Care 2016 · PMID 26740633 · DOI 10.2337/dc15-1816系统综述独立交叉核查已核查摘要★ 关键研究Most studies found no cancer increase; a few suggested more breast cancer, but many studies had design flaws.
Most studies null for any cancer; breast cancer uncertain; methodological flaws common.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Review observational studies on insulin analogues and cancer.
- 研究是如何开展的？
Systematic review.
- 研究了多少人、动物或样本？
19 studies.
- 实际发现了什么？
13/15 null for any cancer; 4/13 positive for breast cancer.
- 观察到的效应有多大？
Not pooled.
- 研究结果对日常生活意味着什么？
No clear cancer risk; breast cancer still uncertain.
- 该研究有哪些局限？
Short follow-up in included studies.
- 它对 Elawady 的具体说法说明了什么？
Does not support dose-dependent cancer; leaves breast question open.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Cannot settle long-term breast cancer risk.
-
Glargine, prior insulin use and breast cancer
Peeters PJ et al.. Acta Oncol 2016 · PMID 27150973 · DOI 10.3109/0284186X.2016.1155736队列研究独立交叉核查已核查摘要★ 关键研究Women starting with glargine had no extra breast cancer even after 5 years; a raised risk appeared only in women with long prior use of other insulins.
No glargine-duration effect in insulin-naive women; signal only in switchers with long prior insulin.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Relate glargine duration to breast cancer.
- 研究是如何开展的？
UK cohort.
- 研究了多少人、动物或样本？
12,468 women.
- 实际发现了什么？
No effect in new users; HR 3.17 in long-term switchers.
- 观察到的效应有多大？
HR 1.06 (new users >=5 y).
- 研究结果对日常生活意味着什么？
Glargine itself is unlikely to be the cause.
- 该研究有哪些局限？
Few cases.
- 它对 Elawady 的具体说法说明了什么？
Weakens the breast-cancer claim for glargine.
- 研究结果是否适用于德国和欧洲？
UK data.
- 从该研究中明确不能得出什么结论？
Cannot explain the switcher signal.
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
The signal came from German data (AOK) and was reviewed by European regulators in 2009 (EMA statement not fetched in this audit; verified: false). Glargine remains approved in the EU.
埃及
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
在我的国家适用什么？
一般科学评估
基本错误 甘精胰岛素不会以剂量依赖的方式增加总体癌症风险；英国部分分析中可能出现的长期乳腺癌信号，未能在更大规模的新用药者研究中得到证实。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes.. Wu JW et al.. J Clin Oncol 2017 · PMID 28953430 · DOI 10.1200/JCO.2017.73.4491
- Basal insulin and cardiovascular and other outcomes in dysglycemia.. ORIGIN Trial Investigators; Gerstein HC et al.. N Engl J Med 2012 · PMID 22686416 · DOI 10.1056/NEJMoa1203858
- The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia.. Bordeleau L et al.. Diabetes Care 2014 · PMID 24574355 · DOI 10.2337/dc13-1468
- Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.. Tang X et al.. PLoS One 2012 · PMID 23284776 · DOI 10.1371/journal.pone.0051814
- Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins.. Bradley MC et al.. Diabetes Care 2020 · PMID 32075848 · DOI 10.2337/dc19-0614
- Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms.. Calle EE et al.. Nat Rev Cancer 2004 · PMID 15286738 · DOI 10.1038/nrc1408
- Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.. Hemkens LG et al.. Diabetologia 2009 · PMID 19565214 · DOI 10.1007/s00125-009-1418-4
- Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden.. Jonasson JM et al.. Diabetologia 2009 · PMID 19588120 · DOI 10.1007/s00125-009-1444-2
- Long-term effects of insulin glargine on the risk of breast cancer.. Suissa S et al.. Diabetologia 2011 · PMID 21614572 · DOI 10.1007/s00125-011-2190-9
- Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies.. Wu JW et al.. Diabetes Care 2016 · PMID 26740633 · DOI 10.2337/dc15-1816
- Insulin glargine use and breast cancer risk: Associations with cumulative exposure.. Peeters PJ et al.. Acta Oncol 2016 · PMID 27150973 · DOI 10.3109/0284186X.2016.1155736